Patents by Inventor Christine Tkaczyk
Christine Tkaczyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970527Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.Type: GrantFiled: September 23, 2021Date of Patent: April 30, 2024Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
-
Patent number: 11578119Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: GrantFiled: June 7, 2021Date of Patent: February 14, 2023Assignees: MedImmune LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Patent number: 11447543Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: GrantFiled: July 9, 2020Date of Patent: September 20, 2022Assignee: MedImmune, LLCInventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
-
Publication number: 20220089699Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.Type: ApplicationFiled: October 1, 2021Publication date: March 24, 2022Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
-
Publication number: 20220073595Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.Type: ApplicationFiled: September 23, 2021Publication date: March 10, 2022Inventors: Christine TKACZYK, Bret SELLMAN, Martin BORROK, III, Davide CORTI, Andrea MINOLA
-
Publication number: 20210363229Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: ApplicationFiled: June 7, 2021Publication date: November 25, 2021Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Davide CORTI, Andrea MINOLA
-
Patent number: 11168133Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.Type: GrantFiled: October 8, 2019Date of Patent: November 9, 2021Assignee: MedImmune, LLCInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Taylor Cohen
-
Patent number: 11155606Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.Type: GrantFiled: July 24, 2019Date of Patent: October 26, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
-
Patent number: 11059884Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: GrantFiled: October 8, 2019Date of Patent: July 13, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Publication number: 20200407429Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: ApplicationFiled: July 9, 2020Publication date: December 31, 2020Applicant: MedImmune, LLCInventors: Bret SELLMAN, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
-
Patent number: 10759849Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.Type: GrantFiled: October 11, 2019Date of Patent: September 1, 2020Assignee: MEDIMMUNE, LLCInventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
-
Patent number: 10730934Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: GrantFiled: January 25, 2018Date of Patent: August 4, 2020Assignee: Medlmmune, LLCInventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
-
Publication number: 20200109189Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (C1fA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.Type: ApplicationFiled: October 8, 2019Publication date: April 9, 2020Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
-
Publication number: 20200109191Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.Type: ApplicationFiled: October 11, 2019Publication date: April 9, 2020Applicant: MedImmune, LLCInventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
-
Publication number: 20200109190Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: ApplicationFiled: October 8, 2019Publication date: April 9, 2020Inventors: Christine TKACZYK, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Publication number: 20200048330Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.Type: ApplicationFiled: July 24, 2019Publication date: February 13, 2020Inventors: CHRISTINE TKACZYK, BRET SELLMAN, MARTIN BORROK, III, DAVIDE CORTI, ANDREA MINOLA
-
Patent number: 10457724Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.Type: GrantFiled: December 18, 2017Date of Patent: October 29, 2019Assignee: MedImmune, LLCInventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
-
Publication number: 20190016787Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: ApplicationFiled: January 25, 2018Publication date: January 17, 2019Applicant: MEDIMMUNE, LLCInventors: Bret SELLMAN, Christine TKACZYK, Partha S. CHOWDHURY, Lei HUA, Peter PAVLIK, Rebecca BUONPANE, Chew-Shun CHANG
-
Publication number: 20190002540Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.Type: ApplicationFiled: December 18, 2017Publication date: January 3, 2019Applicant: MedImmune, LLCInventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
-
Patent number: 9879070Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: GrantFiled: November 6, 2013Date of Patent: January 30, 2018Assignee: MedImmune, LLCInventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang